Cited by 1,069Liver Disease Diagnosis and TreatmentLipid metabolism and biosynthesisLipid metabolism and disorders

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease

Open access

Lambert, Jennifer E., Ramos–Roman, Maria A., Browning, Jeffrey D., Parks, Elizabeth J.·2014·Gastroenterology

DOI 10.1053/j.gastro.2013.11.049PMC PMC6276362

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims There have been few studies of the role of de novo lipogenesis in the development of nonalcoholic fatty liver disease (NAFLD). We used isotope analyses to compare de novo lipogenesis and fatty acid flux between subjects with NAFLD and those without, matched for metabolic factors (controls).Methods We studied subjects with metabolic syndrome and/or levels of alanine aminotransferase and aspartate aminotransferase >30 mU/L, using magnetic resonance spectroscopy to identify those with high levels (HighLF, n = 13) or low levels (LowLF, n = 11) of liver fat. Clinical and demographic information was collected from all participants, and insulin sensitivity was measured using the insulin-modified intravenous glucose tolerance test. Stable isotopes were administered and gas chromatography with mass spectrometry was used to analyze free (nonesterified) fatty acid (FFA) and triacylglycerol flux and lipogenesis.Results Subjects with HighLF (18.4% ± 3.6%) had higher plasma levels of FFAs during the nighttime and higher concentrations of insulin than subjects with LowLF (3.1% ± 2.7%; P = .04 and P < .001, respectively). No differences were observed between groups in adipose flux of FFAs (414 ± 195 μmol/min for HighLF vs 358 ± 105 μmol/min for LowLF; P = .41) or production of very-low-density lipoprotein triacylglycerol from FFAs (4.06 ± 2.57 μmol/min vs 4.34 ± 1.82 μmol/min; P = .77). In contrast, subjects with HighLF had more than 3-fold higher rates of de novo fatty acid synthesis than subjects with LowLF (2.57 ± 1.53 μmol/min vs 0.78 ± 0.42 μmol/min; P = .001). As a percentage of triacylglycerol palmitate, de novo lipogenesis was 2-fold higher in subjects with HighLF (23.2% ± 7.9% vs 10.1% ± 6.7%; P < .001); this level was independently associated with the level of intrahepatic triacylglycerol (r = 0.53; P = .007).Conclusions By administering isotopes to subjects with NAFLD and control subjects, we confirmed that those with NAFLD have increased synthesis of fatty acids. Subjects with NAFLD also had higher nocturnal plasma levels of FFAs and did not suppress the contribution from de novo lipogenesis on fasting. These findings indicate that lipogenesis might be a therapeutic target for NAFLD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2013.11.049

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citation
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Self-citation
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Banting Lecture 2001
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
Charlton, M., Burns, J. M., Pedersen, R. A., Watt, K. D. S., Heimbach, J. K., & Dierkhising, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.061 · Cited by 1,115
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a.
Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., & Goldstein, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118951 · Cited by 817

Show all 58 references

Sorted by citations

Items 301–400 of 998

Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway
Zhang, C., Hu, J., Sheng, L., Yuan, M., Wu, Y., Chen, L., Wang, G., & Qiu, Z. (2019) · Food & Function · doi:10.1039/c9fo00284g · Cited by 57
High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths
Chiara, F. D., Checcllo, C. U., & Ramón‐Azcón, J. (2019) · Nutrients · doi:10.3390/nu11122985 · Cited by 58
“IR induces an increase in DNL which contribute to synthesis and accumulation of TG in the liver [75,76].”
Background
Ablation of prolactin receptor increases hepatic triglyceride accumulation
Shao, S., Yao, Z., Lu, J., Song, Y., He, Z., Yu, C., Zhou, X., Zhao, L., Zhao, J., & Gao, L. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.048 · Cited by 56
Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?
Ipsen, D. H., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa081 · Cited by 59
“Furthermore, hepatic gene expression patterns suggest that the pathogenesis is different, as MCD models exhibit suppressed de novo lipogenesis (92, 93) in contrast to the enhanced de novo lipogenesis reported in patients (38, 94, 95).”
Result
Role of diet on non-alcoholic fatty liver disease: An updated narrative review
Papandreou, D. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.575 · Cited by 55
Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: The alleviating effect and its mechanism of Polygonatum kingianum.
Yang, X.-X., Wang, X., Shi, T.-T., Dong, J., Li, F.-J., Zeng, L., Yang, M., Gu, W., Li, J.-P., & Yu, J. (2019) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2019.109083 · Cited by 48
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
Beysen, C., Schroeder, P. E., Wu, E., Brevard, J. A., Ribadeneira, M. D., Lu, W., Dole, K., O’Reilly, T. E., Morrow, L., Hompesch, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14272 · Cited by 55
“DNL-derived lipids may also contribute to the accumulation of fatty acid metabolites causing lipotoxic hepatocellular injury6 and the upregulation of inflammatory pathways.7,8 Reducing hepatic DNL could therefore be an attractive treatment target for NASH.”
BackgroundInfluential
Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence
Jeyakumar, S. M., & Vajreswari, A. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i1.168 · Cited by 56
Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy
Arrese, M. A., Cortés, V., Francisco Barrera, M., & Nervi, F. O. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000416 · Cited by 54
Hepatic Slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2 diabetes
Liu, Y., Lin, H., Jiang, L., Shang, Q., Yin, L., Lin, J. D., Wu, W., & Rui, L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci128073 · Cited by 53
“However, excessive lipogenesis leads to lipotoxicity, and causes (or worsens) devastating human diseases, including fatty liver disease (2, 3).”
Background
Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH
Mucinski, J. M., Salvador, A. F., Moore, M. P., Fordham, T. M., Anderson, J. M., Shryack, G. E., Cunningham, R. P., Lastra, G., Gaballah, A. H., Diaz‐Arias, A. A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.017 · Cited by 58
Self-citation
The association between different insulin resistance surrogates and all-cause mortality and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease
Gao, X., Chen, T., Zhou, F., Sun, Y., Zhang, J., Li, X., Zhao, W., Li, Y., Shi, Y., Niu, K., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02758-w · Cited by 55
“Through stimulating de novo lipogenesis, increasing the influx of free fatty acids into the liver, and impairing fatty acid oxidation, hepatic IR promotes hepatic lipid accumulation [19–21].”
EJE PRIZE 2015: How does insulin resistance arise, and how does it cause disease? Human genetic lessons
Semple, R. K. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1131 · Cited by 57
Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in diet‐induced insulin‐resistant mice
Zhang, F., Hu, Z., Li, G., Huo, S., Ma, F., Cui, A., Xue, Y., Han, Y., Gong, Q., Gao, J., et al. (2018) · Hepatology · doi:10.1002/hep.29926 · Cited by 53
Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression
Azzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
Fouqueray, P., Bolze, S., Dubourg, J., Hallakou‐Bozec, S., Theurey, P., Grouin, J., Chevalier, C., Dagorn, P. G., Moller, D. E., & Cusi, K. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100474 · Cited by 52
“The reduction in DNL may also be predictive of the potential for longer term decreases in liver steatosis because NAFLD and NASH are characterized by substantial increases in DNL.17,37 It would also be of interest to assess fractional DNL in response to typical meal intake rather than only in response to fructose.”
Background
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Fasting Plasma Insulin Concentrations Are Associated With Changes in Hepatic Fatty Acid Synthesis and Partitioning Prior to Changes in Liver Fat Content in Healthy Adults
Pramfalk, C., Pavlides, M., Banerjee, R., McNeil, C. A., Neubauer, S., Karpe, F., & Hodson, L. (2016) · Diabetes · doi:10.2337/db16-0236 · Cited by 51
“The contribution of systemic NEFA to VLDL-TG production has been reported to be similar between insulin-sensitive and insulinresistant individuals (14) and those with and without NAFLD (40,41).”
BackgroundInfluential
A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD
Ashworth, W. B., Davies, N. A., & Bogle, I. D. L. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005105 · Cited by 50
“In vivo, although the majority of hepatic lipids in fatty liver are known to originate from uptake, increases have also been measured in the rates of de novo lipogenesis and triglyceride synthesis [2, 36, 71, 72].”
Background
Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis
Uehara, K., Sostre‐Colón, J., Gavin, M. J., Santoleri, D., Leonard, K., Jacobs, R. L., & Titchenell, P. M. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.015 · Cited by 54
“This key finding is in agreement with previous studies that observed increased AKT and mTORC1 activation in models of ob/ob (Figure 1A) and diet-induced obesity, in which enhanced DNL is a key feature of patients with early-stage NAFL.13-15,35,39,40 These data are consistent with studies that observed enhanced liver d…”
Background
Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives
Yu, X.-D., & Wang, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115157 · Cited by 54
Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma
Liu, J., Sun, B., Guo, K., Yang, Z., Zhao, Y., Gao, M., Yin, Z., Jiang, K., Dong, C., Gao, Z., et al. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00510-0 · Cited by 50
Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver Disease
Wruck, W., Graffmann, N., Kawala, M.-A., & Adjaye, J. (2016) · Stem Cells · doi:10.1002/stem.2454 · Cited by 50
Western Diet Causes Obesity-Induced Nonalcoholic Fatty Liver Disease Development by Differentially Compromising the Autophagic Response
Simões, I. C. M., Karkucińska‐Więckowska, A., Janikiewicz, J., Szymańska, S., Pronicki, M., Dobrzyń, P., Dąbrowski, M., Dobrzyń, A., Oliveira, P. J., Zischka, H., et al. (2020) · Antioxidants · doi:10.3390/antiox9100995 · Cited by 50
“Additionally, dietary sugars containing fructose, primarily metabolized in the liver, contribute to the marked increase in DNL in NAFLD patients [23].”
Background
Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology
Amin, N. B., Saxena, A. R., Somayaji, V., & Dullea, R. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.008 · Cited by 48
Insulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
Changes in body composition and metabolic disease risk
Pi-Sunyer, X. (2018) · European Journal of Clinical Nutrition · doi:10.1038/s41430-018-0320-x · Cited by 53
Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice
Guarino, M., Kumar, P., Felser, A., Terracciano, L., Guixé‐Muntet, S., Humar, B., Foti, M., Nuoffer, J., St–Pierre, M. V., & Dufour, J. (2020) · Cancers · doi:10.3390/cancers12061407 · Cited by 48
“Increased lipogenesis de novo was not a feature of our CD-HFD experimental model [26], since lipogenic enzymes were downregulated (Figure 5).”
Background
Perturbation of the circadian clock and pathogenesis of NAFLD
Mukherji, A., Dachraoui, M., & Baumert, T. F. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154337 · Cited by 53
“Furthermore, excessive TG is transported out of the hepatocytes by binding to liver-produced VLDL and, with impaired β-oxidation or TG transport, the capacity of the liver to clear accumulated TG is compromised, which further contributes to the development of NAFLD [30,31,45].”
Background
De novo lipogenesis is essential for platelet production in humans
Kelly, K. L., Reagan, W. J., Sonnenberg, G. E., Clasquin, M. F., Hales, K. J., Asano, S. M., Amor, P. A., Carvajal‐Gonzalez, S., Shirai, N., Matthews, M. D., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00272-9 · Cited by 49
The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?
Dongiovanni, P., Rametta, R., Meroni, M., & Valenti, L. V. C. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1110018 · Cited by 48
Switching obese mothers to a healthy diet improves fetal hypoxemia, hepatic metabolites, and lipotoxicity in non-human primates
Wesolowski, S. R., Mulligan, C. M., Janssen, R. C., Baker, P. R., Bergman, B. C., D’Alessandro, A., Nemkov, T. G., Maclean, K. N., Jiang, H., Dean, T. A., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.008 · Cited by 48
“showed that hepatic DNL is increased, independent of contributions from dietary fat and plasma free fatty acids to hepatic lipids [58].”
Background
Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review
Głuszyńska, P., Lemancewicz, D., Dzięcioł, J. B., & Hady, H. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245721 · Cited by 51
“Among dietary factors, fructose seems to have an important role, as it is both a substrate and an inducer for de novo hepatic lipogenesis [18].”
Background
Polydatin, A Glycoside of Resveratrol, Is Better Than Resveratrol in Alleviating Non-alcoholic Fatty Liver Disease in Mice Fed a High-Fructose Diet
Zhao, G., Yang, L., Zhong, W., Hu, Y., Tan, Y., Ren, Z., Ban, Q., Yang, C. S., Wang, Y., & Wang, Z. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.857879 · Cited by 49
Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis
Kang, H., You, H. J., Lee, G., Lee, S. H., Yoo, T., Choi, M., Joo, S. K., Park, J. H., Chang, M. S., Lee, D. H., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2078612 · Cited by 47
“them, DNL contributes up to 26% of the total triglycerides (TG) synthesis in NAFLD patients with hyperinsulinemia, while serum-derived non-esterified fatty acids account for approximately 59% and the diet account for 15%;(8) the rate of DNL is three times higher in NAFLD patients than in body mass index (BMI)matched h…”
Background
Hepatic fatty acid synthesis and partitioning: the effect of metabolic and nutritional state
Hodson, L. (2018) · Proceedings of The Nutrition Society · doi:10.1017/s0029665118002653 · Cited by 49
Green tea polyphenols attenuate hepatic steatosis, and reduce insulin resistance and inflammation in high-fat diet-induced rats
Xia, H., Wang, J., Xie, X., Xu, L., & Tang, S. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4285 · Cited by 47
Perspectives on youth‐onset nonalcoholic fatty liver disease
Castillo‐Leon, E., Cioffi, C. E., & Vos, M. B. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.184 · Cited by 45
“36 Among the different process involved in NAFLD pathogenesis, DNL has been shown to be substantially increased in patients with NAFLD, 37,38 and is the major contributor of intrahepatic triglycerides (nearly 40% of plasma triglyceride-rich lipoprotein triglycerides in adults with NAFLD and…”
Background
Branched-chain and aromatic amino acids, insulin resistance and liver specific ectopic fat storage in overweight to obese subjects
Haufe, S., Witt, H., Engeli, S., Kaminski, J., Utz, W., Fuhrmann, J. C., Rein, D., Schulz‐Menger, J., Luft, F. C., Boschmann, M., et al. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.013 · Cited by 47
Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study
Lai, H. T. M., Otto, M. C. D. O., Lee, Y., Wu, J. H. Y., Song, X., King, I. B., Psaty, B. M., Lemaître, R. N., McKnight, B., Siscovick, D. S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012881 · Cited by 46
Emerging Roles of Calcium Signaling in the Development of Non-Alcoholic Fatty Liver Disease
Chen, C.-C., Hsu, L., Chen, K., Chiu, K., Chen, C., & Huang, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010256 · Cited by 47
“The liver is also capable of generating fatty acids through de novo lipogenesis (DNL), a process by which carbohydrates, especially fructose, are converted to fatty acids [5].”
Background
Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
Holzner, L. M. W., & Murray, A. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.753268 · Cited by 45
Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH
Li, Y., Xie, Z., Song, Q., & Li, J.-Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00864-z · Cited by 49
“0% from dietary intake, which were traced using orally fed stable isotopes in humans, and the DNL rate is up to three-fold higher in NAFLD patients than healthy humans [111, 112].”
Background
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis
Khoo, N. K. H., Fazzari, M., Chartoumpekis, D. V., Li, L., Guimarães, D. A., Arteel, G. E., Shiva, S., & Freeman, B. Α. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101132 · Cited by 46
Altered branched-chain α-keto acid metabolism is a feature of NAFLD in individuals with severe obesity
Grenier–Larouche, T., Kwee, L. C., Deleye, Y., León‐Mimila, P., Walejko, J. M., McGarrah, R. W., Marceau, S., Trahan, S., Racine, C., Carpentier, A. C., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159204 · Cited by 48
“These findings demonstrate that higher plasma levels of BCKA and hepatic expression of BCKDK are features of human NAFLD/NASH and identify SREBP1 as a transcriptional regulator of BCKDK. JCI Insight 2022;7(15):e159204 https://doi.org/10.1172/jci.insight.159204 export in VLDLs, and hepatic rates of β oxidation and keto…”
BackgroundInfluential
The chromatin remodeling protein BRG1 regulates APAP-induced liver injury by modulating CYP3A11 transcription in hepatocyte
Li, N., Kong, M., Zeng, S., Xu, Z., Li, M., Hong, W., Chu, X., Sun, X., Zhu, M., & Xu, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.003 · Cited by 44
A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes
Saxena, A. R., Lyle, S., Khavandi, K., Qiu, R., Whitlock, M., Esler, W. P., & Kim, A. M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14946 · Cited by 44
“However, despite modest reductions in FPG, PF06835919 did not appear to significantly lower HbA1c, as no clear difference in HbA1c, compared with placebo, was observed for either PF-06835919 150 or 300 mg. HbA1c is an indicator of long-term glycaemic control, and elevated levels correlate with an increased risk of dia…”
BackgroundInfluential
Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis
Alamri, H., Patterson, N. H., Yang, E., Zoroquiaín, P., Lazaris, A., Chaurand, P., & Metrakos, P. P. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1506-8 · Cited by 44
“While the adipose tissue contributes the majority of FFAs in the liver [7], tracer studies on matched controls with or without hepatic steatosis showed no difference in the adipose tissue contribution to the hepatic lipid pool [14].”
Influential
Mitochondrial Transfer by Human Mesenchymal Stromal Cells Ameliorates Hepatocyte Lipid Load in a Mouse Model of NASH
Hsu, M.-J., Karkossa, I., Schäfer, I., Christ, M., Kühne, H., Schubert, K., Rolle-Kampczyk, U. E., Kalkhof, S., Nickel, S., Seibel, P., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8090350 · Cited by 43
“Taken together, the pathobiochemical changes in the mouse liver upon MCD diet feeding are in line with major features of NASH as described [85,86].”
Background
Population-based plasma lipidomics reveals developmental changes in metabolism and signatures of obesity risk: a mother-offspring cohort study
Mir, S. A., Chen, L., Burugupalli, S., Burla, B., Ji, S., Smith, A., Narasimhan, K., Ramasamy, A., Tan, K. M. L., Huynh, K., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02432-y · Cited by 43
“Previous studies have shown DNL in obese subjects can lead to lipotoxicity and metabolic disease [64, 65].”
Background
Perilipins: A family of five fat‐droplet storing proteins that play a significant role in fat homeostasis
Chandrasekaran, P., Weiskirchen, S., & Weiskirchen, R. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30579 · Cited by 47
“12,13 As a result, these pathways become dysregulated or impaired, leading to an accumulation of lipid droplets in hepatocytes and an increase in PLIN proteins.”
Background
Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 46
Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis
Duwaerts, C. C., & Maher, J. J. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0224-8 · Cited by 42
Metabolic control of gene transcription in non-alcoholic fatty liver disease: the role of the epigenome
Sinton, M. C., Hay, D. C., & Drake, A. J. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0702-5 · Cited by 44
Loss of HMGCS2 Enhances Lipogenesis and Attenuates the Protective Effect of the Ketogenic Diet in Liver Cancer
Wang, Y.-H., Suk, F., & Liao, Y. (2020) · Cancers · doi:10.3390/cancers12071797 · Cited by 44
Nonalcoholic fatty liver disease, circulating ketone bodies and all‐cause mortality in a general population‐based cohort
Post, A., Garcia, E., van den Berg, E. H., Flores-Guerrero, J. L., Gruppen, E. G., Groothof, D., Westenbrink, B. D., Connelly, M. A., Bakker, S. J. L., & Dullaart, R. P. F. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13627 · Cited by 44
Curcumin and dietary polyphenol research: beyond drug discovery
Jin, T. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.179 · Cited by 43
Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis
Lee, S. R., Kwon, S. W., Kaya, P., Lee, Y. H., Lee, J. G., Kim, G., Lee, G.-S., Baek, I.-J., & Hong, E.-J. (2018) · Scientific Reports · doi:10.1038/s41598-018-34148-6 · Cited by 37
Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis
Gabbia, D., Roverso, M., Guido, M., Sacchi, D., Scaffidi, M., Carrara, M., Orso, G., Russo, F. P., Floreani, A., Bogialli, S., et al. (2019) · Nutrients · doi:10.3390/nu11071602 · Cited by 45
“Interestingly, although the histology evidenced the absence of macroscopic alterations, the increases of α-SMA- and CD68-positive cells in the liver, although limited, indicate that a mild activation of HSCs (also confirmed by the increase of α-SMA and Col1A1 mRNA expression in liver tissue, and consistent to what has…”
BackgroundInfluential
MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1
Zhang, M., Tang, Y., Tang, E., & Lu, W. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.143 · Cited by 42
Leptin decreases de novo lipogenesis in patients with lipodystrophy
Baykal, A. P., Parks, E. J., Shamburek, R. D., Syed‐Abdul, M. M., Chacko, S. K., Cochran, E. K., Startzell, M. S., Gharib, A. M., Ouwerkerk, R., Abd‐Elmoniem, K. Z., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137180 · Cited by 44
Self-citation
Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models
Matsukawa, T., Yagi, T., Uchida, T., Sakai, M., Mitsushima, M., Naganuma, T., Yano, H., Inaba, Y., Inoue, H., Yanagida, K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.161282 · Cited by 43
“impaired suppression of DNL during fasting compared with obese individuals without NAFLD (8).”
Influential
Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase
Liu, J. Y., Kuna, R. S., Pinheiro, L. V., Nguyen, P. T., Welles, J. E., Drummond, J. M., Murali, N., Sharma, P. V., Supplee, J., Shiue, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.014 · Cited by 42
ChREBP Reciprocally Regulates Liver and Plasma Triacylglycerol Levels in Different Manners
Iizuka, K., Takao, K., Kato, T., Horikawa, Y., & Takeda, J. (2018) · Nutrients · doi:10.3390/nu10111699 · Cited by 42
“De novo lipogenesis plays an important role in the regulation of hepatic lipid contents [5].”
BackgroundInfluential
Serial Biomarkers of De Novo Lipogenesis Fatty Acids and Incident Heart Failure in Older Adults: The Cardiovascular Health Study
Lee, Y., Lai, H. T. M., Otto, M. C. D. O., Lemaître, R. N., McKnight, B., King, I. B., Song, X., Huggins, G. S., Vest, A. R., Siscovick, D. S., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014119 · Cited by 40
The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
Fathi, M., Alavinejad, P., Haidari, Z., & Amani, R. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126635 · Cited by 41
β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies
Al-Mrabeh, A. H. (2021) · Biomedicines · doi:10.3390/biomedicines9020226 · Cited by 43
“Therefore, the rates of hepatic de novo lipogenesis (DNL) rise substantially in T2DM under elevated levels of glucose and insulin [34,36,37].”
Background
Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice
Bhat, N., Narayanan, A., Fathzadeh, M., Kahn, M., Zhang, D., Goedeke, L., Neogi, A., CARDONE, R. L., Kibbey, R. G., Fernandez-Hernando, C. F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153724 · Cited by 44
“Interestingly, the DNL rates have been shown to be increased 5-fold in individuals with obesity (46) and T2D (47) and up to 3-fold in individuals with NAFLD compared with healthy controls (48).”
Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
Barritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 43
Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis
Hughey, C. C., Puchalska, P., & Crawford, P. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159209 · Cited by 45
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 45
“While the rate of DNL is significantly different between NAFLD and non-NAFLD subjects [30,31], NAFLD is also characterised by increased adipose tissue fatty acid flux and peripheral insulin resistance [31].”
Background
Measurement of lipogenic flux by deuterium resolved mass spectrometry
Fu, X., Deja, S., Fletcher, J. A., Anderson, N. N., MIZERSKA, M. N., do Vale, G. D., Browning, J. D., Horton, J. D., McDonald, J. G., Mitsche, M. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23958-4 · Cited by 40
Self-citation
Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver
Feng, Y., Sun, W., Sun, F., Yin, G., Liang, P., Chen, S., Liu, X., Jiang, T., & Zhang, F. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s386982 · Cited by 41
“Compared with the standard drug, natural compounds do not need synthetic, readily available.132 Although the role of these natural compounds in vivo or in vitro was widely studied, clinical application research is still less, and future research can be aimed at improving pharmacokinetic and pharmacodynamic properties…”
Influential
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Semmler, G., Datz, C., & Trauner, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0364 · Cited by 43
Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes
Sargsyan, A., & Herman, M. A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1195-5 · Cited by 42
Experimental models of metabolic and alcoholic fatty liver disease
Buyco, D. G., Martin, J., Jeon, S., Hooks, R., Lin, C., & Carr, R. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i1.1 · Cited by 41
Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease
Poulsen, M. K., Nellemann, B., Stødkilde-Jørgensen, H., Pedersen, S. B., Grønbæk, H., & Nielsen, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3476 · Cited by 39
Towards Understanding the Direct and Indirect Actions of Growth Hormone in Controlling Hepatocyte Carbohydrate and Lipid Metabolism
Vazquez-Borrego, M. C., del Río-Moreno, M., & Kineman, R. D. (2021) · Cells · doi:10.3390/cells10102532 · Cited by 39
Apolipoprotein A4 Restricts Diet‐Induced Hepatic Steatosis via SREBF1‐Mediated Lipogenesis and Enhances IRS‐PI3K‐Akt Signaling
Cheng, C., Liu, X.-H., He, J., Gao, J. X., Zhou, J., Fan, J., Jin, X., Zhang, J., Chang, L., Xiong, Z., et al. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202101034 · Cited by 39
MetALD: Clinical aspects, pathophysiology and treatment
Gratacós‐Ginès, J., Ariño, S., Sancho‐Bru, P., Bataller, R. A., & Pose, E. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101250 · Cited by 45
“64 Similarly, chronic alcohol consumption has been associated with adipose tissue lipolysis, upregulation of hepatic fatty acid transporters and enhanced activity of key lipogenic regulators.”
Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease
Moreno‐Vedia, J., Girona, J., Ibarretxe, D., Masana, L., & Rodríguez‐Calvo, R. (2022) · Biomedicines · doi:10.3390/biomedicines10010197 · Cited by 40
“An increased liver triglyceride content may be due to an enhanced non-esterified fatty acid uptake as a result of an increased lipolysis in adipose tissue mediated by insulin resistance in patients with obesity, metabolic syndrome, or type 2 diabetes, among other conditions [37,38].”
Background
In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions
Zhu, Z., Zhang, X., Pan, Q., Zhang, L., & Chai, J. (2023) · Liver Research · doi:10.1016/j.livres.2023.11.003 · Cited by 38
“13 Thus, DNL may play a crucial role in the development of NAFLD.”
Supplementation of Lycium barbarum Polysaccharide Combined with Aerobic Exercise Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis via AMPK/PPARα/PGC-1α Pathway
Li, D., Ma, J.-M., Li, M., Gao, L., Fan, Y., Zhang, Y., Tao, X., & Yang, J. (2022) · Nutrients · doi:10.3390/nu14153247 · Cited by 40
“In another 12-week trial, 3 mg FASN inhibitor FT-4101 has been shown to reduce hepatic DNL and steatosis [38].”
BackgroundInfluential
Understanding the Link Between Sterol Regulatory Element Binding Protein (SREBPs) and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
Barbhuiya, P. A., Yoshitomi, R., & Pathak, M. P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00626-y · Cited by 44
“This is due to the persistent activation of a protein called SREBP1c, which leads to increased fat production in the liver and the development of hepatic steatosis [72, 73].”
Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets
Umpleby, A. M., Shojaee‐Moradie, F., Fielding, B. A., Li, X., Marino, A., Jawad, N. M. M., Isherwood, C., Jackson, N., Ahmad, A., Stolinski, M., et al. (2017) · Clinical Science · doi:10.1042/cs20171208 · Cited by 41
“M en with NAFL D ha d a higher D NL re l ative to contro l s after the l ow sugars d iet, in accor d with previous reports of increase d contribution of D NL to hepatic fat an d d ys l ipi d aemia in men with NAFL D [ 8 ,26 ] .”
Hepatocyte leukotriene B4 receptor 1 promotes NAFLD development in obesity
Liu, X., Wang, K., Wang, L., Kong, L., Hou, S., Wan, Y., Ma, C., Chen, J., Xing, X., Xing, C., et al. (2022) · Hepatology · doi:10.1002/hep.32708 · Cited by 43
“7%, n = 11).[4] The importance of DNL in NAFLD is further supported by studies showing that in obese patients with NAFLD, approximately 26% of hepatic TG were derived from DNL.”
From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations
Green, C., Pramfalk, C., Morten, K., & Hodson, L. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00192.2014 · Cited by 39
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
Lawitz, E., Li, K. W., Nyangau, E., Field, T., Chuang, J.-C., Billin, A. N., Wang, L., Wang, Y., Huss, R. S., Chung, C., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100250 · Cited by 37
“%EM1slow, t =%ЕМ1t − (ЕМ1∗BW ×%DNLW12 ×%Fast) (3)”
Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade
Lu, Y., Zhang, C., Song, Y., Chen, L., Chen, X., Zheng, G., Yang, Y., Cao, P., & Qiu, Z. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175457 · Cited by 38
Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
Dashti, Z. J. S., Yousefi, Z., Kiani, P., Taghizadeh, M., Maleki, M. H., Borji, M., Vakili, O., & Shafiee, S. M. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155811 · Cited by 38
Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
Kasprzak‐Drozd, K., Niziński, P., Kasprzak, P., Kondracka, A., Oniszczuk, T., Rusinek, A., & Oniszczuk, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073746 · Cited by 39
“Unlike SREBP-1c, ChREBP activation is mediated by glucose, and it also takes part in providing substrates to FFAs and TG synthesis [26].”
Background
The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases
Li, M., Cui, M., Li, G., Liu, Y., Xu, Y., Eftekhar, S. P., & Ala, M. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2266-1503 · Cited by 37
“The combination of increased triglyceride synthesis and decreased fatty acid catabolism contributes to liver fat accumulation and dyslipidemia [52].”
Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long‐chain n‐3 PUFA
Delarue, J., & Lallès, J. P. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500346 · Cited by 37
“It is a condition defined by macro-vesicular steatosis in 5% of hepatocytes Correspondence: Jacques Delarue E-mail: jacques.delarue@univ-brest.fr Abbreviations: ChREBP, carbohydrate regulatory elementbinding protein; DHA, docosahexaenoic acid; DNL, de novo lipogenesis; DSS, dextran sodium sulfate; EPA, eicosapentaenoi…”
Influential
Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models
Green, C., Parry, S. A., Gunn, P. J., Ceresa, C. D. L., Rosqvist, F., Piché, M., & Hodson, L. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0038 · Cited by 40
Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease
Fontes, A., Pagès, M. A. I., Oliveira, P. J., Ramalho‐Santos, J., Zischka, H., & Azul, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163987 · Cited by 38
Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis
Matsumoto, M., Yashiro, H., Ogino, H., Aoyama, K., Nambu, T., Nakamura, S., Nishida, M., Wang, X., Erion, D. M., & Kaneko, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228212 · Cited by 37
“Based on these insights, it appears that triglyceride derived from DNL makes a major contribution to hepatic steatosis; therefore, the inhibition of DNL might be the best approach to suppress or prevent further deterioration of hepatic steatosis [19, 20].”
Background
Mogroside V Protects against Hepatic Steatosis in Mice on a High‐Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation
Li, L., Zheng, W., Wang, C., Qi, J., & Li, H. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/7826874 · Cited by 39
“In an individual with NAFLD, the level of de novo lipogenesis increased more than 3-fold compared with the normal individual [26].”
Background
The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease
Park, G. S. H., Jung, S., Wellen, K. E., & Jang, C. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00614-x · Cited by 37
Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4
Wang, B., Shen, Y., Zhai, L., Xia, X., Gu, H.-M., Wang, M., Zhao, Y., Chang, X., Alabi, A., Xing, S., et al. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100091 · Cited by 37
Determination of Fatty Acid Oxidation and Lipogenesis in Mouse Primary Hepatocytes
Akie, T. E., & Cooper, M. P. (2015) · Journal of Visualized Experiments · doi:10.3791/52982 · Cited by 37

Authors: Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J.
Affiliations: The University of Texas Southwestern Medical Center (US)
Corresponding author: Parks, Elizabeth J.
ORCID: Parks, Elizabeth J.
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2014-03
Volume: 146
Issue: 3
Pages: 726-735
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2013.11.049
PMC: PMC6276362
OpenAlex: W2139351004
Cited by: 1,069
References: 58
Citations by year: 2026: 67 · 2025: 111 · 2024: 110 · 2023: 108 · 2022: 124 · 2021: 111 · 2020: 106 · 2019: 92 · 2018: 75 · 2017: 47 · 2016: 49 · 2015: 45 · 2014: 23
FWCI: 28.42
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (RL1DK081187, UL1DE019584, UL1-RR024982)
National Center for Advancing Translational Sciences (RL1DK081187, UL1DE019584, UL1-RR024982)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: de novo lipogenesis, non-alcoholic fatty liver disease, fatty acid synthesis, triglyceride synthesis, liver fat, metabolic syndrome, insulin sensitivity, stable isotope tracer studies, hepatic lipid metabolism, insulin
MeSH terms: Fatty Acids, Nonesterified, Fatty Liver, Female, Humans, Hyperlipidemias, Liver, Magnetic Resonance Imaging, Male, Comorbidity, Case-Control Studies, Metabolic Syndrome, Lipogenesis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks